新的研究在AAIC 2020颁发了Virtual Alzheimer协会国际会议。以下特征突出了会议中出现的一些研究。

-----------------------


流感疫苗接种和减少的广告发病率

由于预防仍然是对抗阿尔茨海默病(AD)的有价值的方法,由于缺乏有效的治疗,研究人员试图在统计上测试流感疫苗接种和广告之间的关系,希望识别广告预防的候选人。使用患者EHR数据集ICD-9代码,指示广告诊断,并排除比60年龄较小的患者,评估团队评估了疫苗接种和未接种的患者。为了分析疫苗接种频率的影响,它们通过从第一疫苗接种时间戳到AD发作或观察结束的时间长度将疫苗接种数量分​​成疫苗。流感疫苗接种在研究人群中显着降低了患病率(差异率[或],0.8309),流感疫苗的频率对抑制AD发作(或0.8736)而产生显着影响,并且时间分析显示接收的时间分析与在年龄较大的疫苗接受疫苗的疫苗相比时,血液流感疫苗导致了较小的广告风险,患有1年的疫苗接种年龄增加,其危险比为1.0924增加。“该结果提供了证据表明,流感疫苗接种可能是[广告]风险因素的流行病学研究中的混淆因素,”写作作者。

-----------------------

磷酸盐Tau217作为广告的生物标志物

In order to evaluate whether cerebrospinal fluid (CSF) tau phosphorylated at threonine 217 (p-tau217) or plasms p-tau217 are even better biomarkers of Alzheimer’s disease (AD) than p-tau181, study investigators compared CSF p-tau217 and CSF p-tau81 among a cohort of nearly 200 and evaluated plasma p-tau217 and plasma p-tau181 in three cohorts with 1,438 participants. CSF p-tau217 had stronger correlations with the tau-PET tracer, and more accurately identified individuals with abnormal tau-PET scans than CSF P-tau181. CSF P-tau217 correlated better than p-tau181 with CSF and PET measures of neocortical amyloid-β burden and more accurately distinguished AD dementia from non-AD neurodegenerative disorders. Antemortem plasma P-tau217 differentiated individuals with intermediate-to-high likelihood of AD according to neuropathology from those without AD and performed significantly better than plasma P-tau181. Plasma P-tau217 also differentiated clinical AD dementia from non-AD neurodegenerative diseases significantly better than plasma P-tau181, plasma neurofilament light, and established MRI measures, and similar to CSF P-tau217, CSF P-tau181, CSF Aβ42/40, and tau-PET. Increased plasma P-tau217 was observed already in the pre-symptomatic stages of AD. In PSEN1 mutation carriers, the increase started at age 25, about 20 years prior to estimated onset of mild cognitive impairment. Plasma P-tau217 correlated with cerebral tau tangle densities in subjects with neuritic plaques. It predicted abnormal tau-PET scans significantly better than plasma P-tau181, plasma neurofilament light, CSF P-tau181 and CSF Aβ42/Aβ40, and similar to CSF P-tau217.

-----------------------

用于最新消息和更新

早期教育质量和后期痴呆症风险

对于一项研究,研究人员将国家级行政学校质量的指标作为认知下降和痴呆症的预测因素,在以后的生活/性别跨越种族/民族的生命中的痴呆症风险。参与者包括近2,500名男女,在美国上小学出席了21年的美国。调整年龄后,童年社会经济地位和童年住宅状态,发现早期的早期教育质量与所有群体中的语言表现相关,黑人女性的内存表现水平以及记忆中的内存绩效水平相关。非西班牙裔男女和妇女和黑人女性。高等教育质量与非西班牙裔女性和黑人男女的痴呆症风险较低,但在会计协变者之后与非西班牙裔男子的痴呆症风险无关。当模型包括多年的教育时,学校质量对痴呆症风险的影响以及记忆和语言表现的水平和变化,对黑人来说完全衰减,并部分减弱非西班牙裔男女和妇女和黑人女性。“这些调查结果提供了证据表明后期生命脑健康受早期国家教育政策的影响,”写作作者“。

-----------------------


睡眠太少或太多睡眠风险

随着研究表明,睡眠障碍是普遍的,睡眠障碍的普遍性,睡眠健康与脑卫生的复杂联系,调查人员评估了自我报告的睡眠性状,夜间睡眠,白天嗜睡,睡眠呼吸暂停诊断,打鼾和小睡—among more than 500,000 individuals who were free from Alzheimer’s disease (AD) at baseline and follow for up to 12 years. When compared with those who slept an average of 6-9 hours per night, those who slept more than 9 hours had a higher risk of AD (hazard ratio [HR], 2.05) during a mean follow-up of 6.4 years. Sleep apnea (HR, 2.05) and daytime sleepiness (HR, 1.56) also raised the risk for AD significantly, with both remaining predictive of AD after controlling for sleep duration. However, no associations were observed between snoring and AD risk or between napping and AD risk. Among the 932 participants who developed AD during follow-up, the average time to diagnosis was more than 6 years, a possibly “significant window of time to intervene,” said the lead author of the study.

-----------------------

鼓励结果等离子体交换

已经使用了血浆交换处理,几十人用于治疗各种神经系统,免疫和代谢紊乱,治疗包括血浆疫苗,或来自血细胞的分离或血浆和去除或有毒物质。等离子体中的白蛋白,血浆淀粉样蛋白β结合的血浆,是用由健康供体的血浆制成的新鲜白蛋白。研究人员假设,通过将白蛋白与淀粉样蛋白β一起除去并定期用较新的白蛋白替换,它们可能能够从脑脊液中除去淀粉样蛋白β并最终是大脑。为了测试这一假设,他们随机用55-85岁的男性和女性,具有可能的AD痴呆症或三剂白蛋白和静脉注射免疫球蛋白的替代品中的一种(相等的量被除去,除了除去的一半,只取代白蛋白)。6周,参与者收到每周假的假或常规血浆交换治疗2.5-3升血浆,其次是每月12个月,低体积(700-800毫升)等离子体交换或假处理。With no clear differences between the three active-treatment groups, the Alzheimer’s Disease Cooperative Study–Activities of Daily Living scale showed a 52% lower decline in change from baseline to 14 months in the plasma exchange-treated group, when compared with the sham group, while the Alzheimer’s Disease Assessment Scale–Cognitive Subscale showed a 66% lower decline.